Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
S
Syed Hassan Mehdi
Instructor
Also affiliated: Aligarh Muslim University (2013); University of Arkansas Medical Center (2018); Jamia Millia Islamia (2016–2021)
Internal Med, College of Medicine
16 h-index
92 pubs
1,053 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Syed Hassan Mehdi's research investigates the pharmacological effects and potential therapeutic applications of various compounds, with a particular focus on cancer treatment and disease mechanisms. His work includes studying the anti-proliferative and cytotoxic activities of natural compounds and synthesized nanoparticles against different cancer cell lines, including cervical, breast, and colon cancers. Mehdi also examines the impact of these agents on cellular processes like apoptosis and proliferation. His research extends to exploring the protective effects of certain compounds against drug-induced toxicity, such as in cases of hepatotoxicity in animal models. He has published on the therapeutic evolution of benzimidazole derivatives and the synergistic interactions of compounds like rutin and silibinin. Mehdi collaborates extensively with researchers at the University of Arkansas for Medical Sciences, including Donghoon Yoon, Ying-Zhi Xu, Samantha Kendrick, and Vijay Patel, with whom he shares numerous publications. His scholarship metrics include an h-index of 16 and over 1,000 citations across 97 publications.
Metrics
- h-index: 16
- Publications: 92
- Citations: 1,053
Positions
-
Instructor 2019–presentUniversity of Arkansas Medical Center Internal Medicine ORCID
-
Instructor publications 2018–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
Selected Publications
-
M2 Macrophage Polarization Characterizes an Immunosuppressive Microenvironment in Extracranial Arteriovenous Malformations (2026)
-
Abstract LB220: Can dietary calcium prevent myeloma onset (2026)
-
Multimodal microneedle-based electrochemical sensors for continuous monitoring of the tumor microenvironment (2026)
-
Rescue of Angiopoietin‐2 Inhibits Proliferation of Lymphatic Malformation Endothelial Cells (2025)
-
Micropocket-Integrated Microneedle Wound Dressing with PH-Responsive Actuation for Enhanced Drug Delivery (2025)
-
The role of 7-dehydrocholesterol in inducing ER stress and apoptosis of head and neck squamous cell carcinoma (2025)
-
Abstract 1605: Pretreatment of bone anabolic agent delays or prevents multiple myeloma progression (2025)
-
A Pattern-Based Approach to Name and Address Parsing with Active Learning (2025)
-
Mural Cells Initiate Endothelial-to-Mesenchymal Transition in Adjacent Endothelial Cells in Extracranial AVMs (2024)
-
Development of New Diffuse Large B Cell Lymphoma Mouse Models (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- Early Events in Alzheimer Pathogenesis NIH Co-Investigator
Collaboration Network
Top Collaborators
Donghoon Yoon
University of Arkansas for Medical Sciences
14 shared publications
In database
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma
- Animal Models of Multiple Myeloma Bone Disease
- An Improved Animal Model of Multiple Myeloma Bone Disease
- The role of 7-dehydrocholesterol in inducing ER stress and apoptosis of head and neck squamous cell carcinoma
- Development of New Diffuse Large B Cell Lymphoma Mouse Models
Showing 5 of 14 shared publications
Maurizio Zangari
Winthrop Rockefeller Foundation
10 shared publications
In database
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
Showing 5 of 10 shared publications
Frits van Rhee
Winthrop Rockefeller Foundation
9 shared publications
In database
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
Showing 5 of 9 shared publications
Shmuel Yaccoby
Winthrop Rockefeller Foundation
9 shared publications
In database
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
Showing 5 of 9 shared publications
Joshua Epstein
Winthrop Rockefeller Foundation (US)
8 shared publications
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma
Showing 5 of 8 shared publications
Carolina Schinke
Winthrop Rockefeller Foundation
8 shared publications
In database
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma
Showing 5 of 8 shared publications
Sadie Johnson
Winthrop Rockefeller Foundation (US)
8 shared publications
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma
Showing 5 of 8 shared publications
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
8 shared publications
In database
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma
Showing 5 of 8 shared publications
Faith E. Davies
University of Arkansas at Little Rock (US)
6 shared publications
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma
- Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes
Showing 5 of 6 shared publications
Gareth J. Morgan
University of Arkansas for Medical Sciences (US)
6 shared publications
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma
- Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes
Showing 5 of 6 shared publications
A. Moerman
University of Arkansas for Medical Sciences
5 shared publications
In database
- Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma
- Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome
- Normal and Cancer Fibroblasts Differentially Regulate Cytokine Genes and TWIST1 and TOX Expression in Cutaneous T-cell Lymphoma
- Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
- Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Henry K. Wong
University of Arkansas for Medical Sciences
5 shared publications
In database
- Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma
- Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome
- Normal and Cancer Fibroblasts Differentially Regulate Cytokine Genes and TWIST1 and TOX Expression in Cutaneous T-cell Lymphoma
- Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
- Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Wen Ling
Winthrop Rockefeller Foundation
4 shared publications
In database
- EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
- Growth and dormancy control of myeloma cells by mesenchymal stem cells
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
- Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors
Bart Barlogie
Icahn School of Medicine at Mount Sinai
4 shared publications
In database
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma
Pingping Qu
Cancer Research And Biostatistics (US)
4 shared publications
- The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
- Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
- Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma
- Mesenchymal Stem Cells Gene Signature in High-Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2-Expressing Small Adipocytes
Similar Researchers
Based on overlapping research topics
Noemi Garcia Garcia
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Disease Mechanisms Research
R. Eric Davis
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Nawab Ali
University of Arkansas at Little Rock
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Nanoparticles: synthesis and applications
Elena Galitovskaya
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Nanoparticles: synthesis and applications
Daniel Bingham
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Cancer Treatment and Pharmacology
Disease Mechanisms Research
Tariq Fahmi
National Center for Toxicological Research
Pharmacological Effects and Toxicity Studies
Disease Mechanisms Research
Nanoparticles: synthesis and applications